Currently, only an estimated 36 percent of patients with opioid use disorder receive any treatment for their condition due to varying health care access issues. Considering this significant gap, we invite you to register for an upcoming webinar we’re doing in collaboration with APhA, NABP, and NASPA. It’s all about the legal and regulatory developments impacting the prescribing and dispensing of buprenorphine now that the Mainstreaming Addiction Treatment and Medication Access and Training Expansion Acts are law — and you don’t want to miss it. The webinar takes place on Nov. 9 at 1 p.m. ET and you can register here! During the discussion, experts from DEA, NABP, and the White House Office of National Drug Control Policy will address challenges and barriers faced by pharmacists in delivering buprenorphine services, including issues related to stigma, collaboration with other health care practitioners, and suspicious order monitoring programs. Bring your questions to ask our panelists during the open forum portion of our session.
NCPA
